|
Merrill J. Egorin, M.D. is a Professor of Medicine and Pharmacology at the University of Pittsburgh School of Medicine, where he serves as co-director of the Molecular Therapeutics/Drug Discovery Program and director of the Clinical Pharmacology Analytical Facility Core at the University of Pittsburgh Cancer Institute (UPCI).
Dr. Egorin’s research focuses on rational development and application of antineoplastic agents. He serves as principal investigator on a National Cancer Institute-funded contract evaluating the pharmacokinetics, metabolism and pharmacodynamics of antitumor agents being considered for clinical trials, is the principal investigator of a National Cancer Institute-funded cooperative agreement for conducting Phase I studies at UPCI, and is the principal investigator on grants to serve as the pharmacology core for Cancer and Leukemia Group B and for the Gynecologic Oncology Group. Key concepts regularly addressed in Dr. Egorin’s research involve the pharmacokinetics and pharmacodynamic relationships of investigational and licensed antineoplastic agents and how those relationships can be assessed and modeled. | 